Filing Details

Accession Number:
0000899243-20-014715
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-01 16:05:54
Reporting Period:
2020-05-28
Accepted Time:
2020-06-01 16:05:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1596946 Quotient Ltd QTNT In Vitro & In Vivo Diagnostic Substances (2835) 264719797
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1604629 Edward Farrell C/O Quotient Limited
28 Esplanade
St Helier Y9 JE2 3QA
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2020-05-28 12,811 $7.40 29,013 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Ordinary Shares Employee Stock Option (right to buy) $11.92 2026-05-31 30,000 30,000 Direct
Ordinary Shares Employee Stock Option (right to buy) $15.17 2025-05-19 30,000 30,000 Direct
Ordinary Shares Options to acquire ordinary shares $0.00 2023-04-10 96,000 96,000 Direct
Ordinary Shares Employee Stock Option (right to buy) $8.00 2024-04-29 79,000 79,000 Direct
Ordinary Shares Employee Stock Option (right to buy) $7.58 2027-05-23 40,000 40,000 Direct
Ordinary Shares Restricted Stock Units $0.00 12,257 12,257 Direct
Ordinary Shares Restricted Stock Units $0.00 30,000 30,000 Direct
Ordinary Shares Restricted Stock Units $0.00 2,232 2,232 Direct
Ordinary Shares Restricted Stock Units $0.00 55,000 55,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2026-05-31 30,000 30,000 Direct
2025-05-19 30,000 30,000 Direct
2023-04-10 96,000 96,000 Direct
2024-04-29 79,000 79,000 Direct
2027-05-23 40,000 40,000 Direct
12,257 12,257 Direct
30,000 30,000 Direct
2,232 2,232 Direct
55,000 55,000 Direct
Footnotes
  1. Restricted Stock Units convert into ordinary shares on a one-for-one basis.
  2. All 30,000 options have vested and remain exercisable.
  3. All 30,000 options have vested and remain exercisable.
  4. The exercise price will be paid in pounds sterling, at GBP0.003 per share.
  5. All 96,000 options have vested and remain exercisable.
  6. All 79,000 options have vested and remain exercisable.
  7. All 40,000 options have vested and remain exercisable.
  8. On May 24, 2018, the Reporting Person was granted 36,773 Restricted Stock Units, of which 24,516 have vested and have been exercised. The remaining 12,257 Restricted Stock Units will vest on May 24, 2021.
  9. On May 24, 2019, the Reporting Person was granted 45,000 Restricted Stock Units, of which 15,000 have vested and have been exercised. The remaining 30,000 Restricted Stock Units will vest in two equal installments on May 24, 2021 and May 24, 2022.
  10. On January 7, 2020, the Reporting Person was granted 2,232 Restricted Stock Units, vesting in three equal annual installments beginning January 7, 2021.
  11. On May 24, 2020, the Reporting Person was granted 55,000 Restricted Stock Units, vesting in three equal annual installments beginning May 24, 2021.
  12. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2020.
  13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.32 to $7.53, inclusive. The Reporting Person undertakes to provide to Quotient Limited and any security holder of Quotient Limited, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (13) to this Form 4.